The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience

[1]  A. Limper,et al.  Pneumocystis pneumonia in patients treated with rituximab. , 2013, Chest.

[2]  A. Zelenetz,et al.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. , 2013, Clinical lymphoma, myeloma & leukemia.

[3]  L. Kjeldsen,et al.  Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. , 2013, Blood.

[4]  M. Michaels,et al.  Epstein–Barr Virus Infection and Posttransplant Lymphoproliferative Disorder , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  B. Alcázar,et al.  Repeated Aspergillus isolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection? , 2012, BMC Infectious Diseases.

[6]  R. Porcher,et al.  Increased Infection Rate After Preemptive Rituximab Treatment for Epstein-Barr Virus Reactivation After Allogeneic Hematopoietic Stem-Cell Transplantation , 2012, Transplantation.

[7]  L. Piccio,et al.  Rituximab combination therapy in relapsing multiple sclerosis , 2012, Therapeutic advances in neurological disorders.

[8]  W. Klapper,et al.  Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.

[9]  R. Gascoyne,et al.  A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. , 2012, Blood.

[10]  R. Fanin,et al.  Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. , 2012, Blood.

[11]  O. Shpilberg,et al.  Neutropenia after rituximab treatment: new insights on a late complication , 2012, Current opinion in hematology.

[12]  G. Ippolito,et al.  Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis , 2011, BMC medicine.

[13]  F. Breedveld,et al.  Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2011, Annals of the Rheumatic Diseases.

[14]  M. Pistello,et al.  Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. , 2010, The oncologist.

[15]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[16]  L. Qiu,et al.  Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single‐institution experience , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[18]  E. Kimby,et al.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Rostaing,et al.  Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  H. Harputluoglu,et al.  Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis , 2009, Leukemia & lymphoma.

[21]  J. Palmblad,et al.  Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis , 2008, Medical oncology.

[22]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[23]  M. Dougados,et al.  Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials , 2008, Annals of the rheumatic diseases.

[24]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[25]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[27]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Raspe,et al.  Empfehlungen zur Begutachtung klinischer Studien durch Ethik-Kommissionen , 2012 .

[29]  M. Matsumoto,et al.  Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone , 2011, International journal of hematology.

[30]  R. Fonseca,et al.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. , 2010, The Lancet. Oncology.

[31]  J. Styczyński,et al.  Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT , 2009, Bone Marrow Transplantation.

[32]  C. Andrzejewski,et al.  BMC Infectious Diseases , 2006 .

[33]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.